Download Free Sample
Buy Now
Market Size
The biologics safety testing market size, valued at USD 4.9 billion in 2025, is projected to reach USD 5.3 billion in 2026 and USD 9.4 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035.
See What’s in the Full Report–Request Your Complimentary Insights!
Market Report: Key Takeaways
- Driven by the increased usage of biologics safety testing consumables for detecting and identifying contaminants in biologics, the consumable dominates the biologics safety testing market.
- In terms of type of testing, the virus safety testing segment secures majority share by revenue owing to the fact that biologics are highly susceptible to viral contamination, and specialized virus safety testing has become essential to ensure biologic product safety and regulatory compliance in this industry.
- In terms of type of modality, the antibodies segment is likely to capture the majority of the revenue share.
- In terms of type of technology, the polymerase chain reaction segment is likely to capture highest share in the overall biologics safety testing market size.
- In terms of end-user, the pharmaceutical and biotechnology companies segment accounts for around 50% of the overall revenue share.
- In terms of geographical regions, North America is holding close to 40% of the market share due to its strong public and private investments, supportive regulations, and significant funding initiatives that propel regional growth.
Market Overview
Biologics are complex therapeutic molecules composed of various biomolecules, such as carbohydrates, proteins, nucleic acids or a combination of these substances. They are typically produced by living cells, and are highly sensitive to environmental factors, including light, temperature, pH, and oxygen levels.
Due to their structural complexity and biological origin, biologics can pose several safety risks, such as immunogenicity (unwanted immune responses), contamination, and batch-to-batch variability. To address these concerns, safety testing plays a critical role in ensuring that these therapeutic molecules are free from harmful contaminants, consistently effective, and safe for human use. Consequently, biologics safety testing is a rigorous process designed to ensure biologic safety, purity, potency, and consistency before clinical use or market release.
Recent Developments
- In April 2025, Clean Cells acquired Karyologic in order to expand its offerings related to biologics in the US market.
- In April 2025, Texcell presented in the PDA Virus Forum 2025, held at Gothenburg, Sweden. The key topics covered in this conference include, viral safety of biopharmaceuticals, best practices for viral inactivation, filtration to improve manufacturing safety.
- In February 2025, Charles River Laboratories collaborated with Singapore General Hospital in order to provide cell line characterization and next generation sequencing testing services to develop novel therapeutics for cancer patients.
Biologics Safety Testing Market Trends
- Partnerships and Collaborations: The biologics safety testing industry has witnessed a notable number of partnerships, which is likely to drive the growth in this market. For instance, market players, such as Charles River Laboratories and Bionique, are forging various collaborations to expand the development of their biological safety testing solutions. Likewise, several players have entered into various partnerships to jointly offer comprehensive testing to strengthen their position in this market.
- Funding and Investments: Since 2021, over USD 5.2 billion has been raised in the biologics safety testing domain. This is reflective of the growing interest of companies engaged in the development of biological safety testing solutions worldwide. It is worth noting that majority of the funds have been raised through venture capital and other equity rounds. In terms of the funding amount raised, Labcorp raised the maximum funding amount (USD 2 billion) through senior notes public offering.
- Increase in Number of Patents Related to Biologics Safety Testing: In the past few years, several patents have been granted / filed, demonstrating efforts of researchers in this domain. Notably, majority of the patents in this domain include patent applications (43%), followed by granted patents (24%). Interestingly, most of the patents (95%) are filed by industry players in this field.
Have Questions? Let’s Get Them Answered.
Industry Experts on Biologics Safety Testing Market
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
- Business Development Officer, Mid-sized Organization, Austria
- Business Development Director, Mid-sized Organization, Poland
In addition, the market report includes transcripts of the following other third-party discussions:
- R&D Scientist and Product Manager, Very Large Organization, Germany
- Scientific Expert, Very Large Organization, United States
Market Drivers
- Rising Demand for Biologics: The growing demand for biologics and advanced therapies necessitates the need for extensive biologics safety testing. Since biologics are derived from living systems, they are highly sensitive to contamination; therefore, rigorous testing protocols are critical to ensure product integrity, patient safety, and compliance with regulatory standards.
- Technological Advancements: Advanced technologies, such as Next Generation Sequencing (NGS) can significantly improve accuracy, sensitivity, and efficiency of safety testing workflows. Such technologies enable faster detection and identification of impurities, contaminants, and safety risks in biologic products which helps in building a better understanding of these complex large molecules.
- Supportive Regulatory Frameworks: Regulatory agencies are increasingly recognizing the need for advanced safety testing protocols for the rigorous evaluation of biologic products. Therefore, they are imposing comprehensive guidelines that require extensive testing for contaminants, immunogenicity, viral safety, and consistency in biologics manufacturing.
Market Segmentation Analysis
Consumables Driving the Biologics Safety Testing Industry
- According to the biologics safety testing market analysis, the consumables sub-segment dominates the market (60%), driven by the increased demand for consumables, essential for biologics safety testing.
- Instruments are likely to grow at a higher CAGR, showcasing substantial growth potential during the forecast period. This is because the adoption of instruments can streamline the overall workflow and reduce human error.
Want Information on Specific Region / Segment?
Virus Safety Testing are Propelling the Biologics Safety Testing Domain
- According to the biologics safety testing market forecast, the virus safety testing sub-segment dominates the market (~30%), driven by the rising prevalence of chronic diseases and expanding adoption of innovative biologic therapies.
- Mycoplasma testing is likely to grow at a higher CAGR, showcasing substantial growth potential during the forecast period. This is primarily due to the strict regulatory guidelines that mandate rigorous mycoplasma contamination testing in biologics manufacturing.
Rising Antibodies Demand Propelling Innovations in Biologics Safety Testing Solutions
- According to the market, the antibodies sub-segment holds ~35% biologics safety testing market share.
- This dominance is primarily due to their high specificity, versatility, and proven efficacy. Also, they have a broad range of therapeutic applications, including oncology, autoimmune diseases, and infectious diseases, which necessitates their need for biological safety testing.
- Vaccines are likely to grow at a higher CAGR, showcasing substantial growth potential during the forecast period. This growth is due to the increasing approvals of vaccines and their ongoing exploration across diverse target indications.
Polymerase Chain Reaction Drive Growth in Biologics Safety Testing Market
- The global market is segmented across different types of technologies, such as polymerase chain reaction, traditional techniques, chromatographic and electrophoretic techniques, next-generation sequencing and other technologies. The polymerase chain reaction sub-segment captures majority biologics safety testing market share (~35%) in current year.
- This is because recent innovations in polymerase chain reaction technology enable higher accuracy, absolute quantification, and multiplex detection of targets, thereby enhancing testing efficiency and reliability.
- Further, the ease of automating PCR technologies for high-throughput screening, enabling simultaneous detection of multiple contaminants. Such automation improves operational efficiency and reduces testing costs for biological safety testing labs.
Pharmaceutical and Biotechnology Companies Set to Lead Biologics Safety Testing Industry
- According to the biologics safety testing market analysis, the increasing adoption of advanced molecular testing technologies will likely help pharmaceutical and biotechnology companies dominate with considerable biologics safety testing market size (with ~50% share) the market in 2026.
- This is because they have strong research and development (R&D) capabilities, substantial capital investments, and robust pipelines of innovative biologics tailored to address the increasing global burden of health challenges.
- Pharmaceutical and biotechnology companies are likely to grow at a higher CAGR (7.8%), showcasing substantial growth potential during the forecast period.
Regional Market Insights
North America Dominates the Market
In 2035, North America will likely dominate, capturing around 40% of the market share. Key factors that contribute to the region’s dominance in this industry include robust partnerships between stakeholders and cutting-edge manufacturing capabilities for biologics safety testing solutions.
Biologics Safety Testing Solutions Adoption in the Middle East and North Africa Region
The market in Middle East and North Africa is likely to observe biologics safety testing market growth of 7.5% in the forecast period. The detailed methodology across the market and revenue generated across various segments is available in the full report.
Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed
Biologics Safety Testing Market: Scope of the Report
| Key Report Attributes | Details | |
| Historical Trend | Since 2021 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | USD 5.3 Billion | |
| Market Size 2035 | USD 9.4 Billion | |
| CAGR (Till 2035) | 6.6% | |
| Key Players Profiled |
(A complete list of companies captured is available in the report) |
|
| Segments Covered |
|
|
| Excel Data Packs (Complimentary) |
|
|
| PowerPoint Presentation (Complimentary) | Available | |
| Customization Scope | Since 2020 | |
Market Segments
Based on the research, we have segmented the Biologics Safety Testing Market into type of offering, type of testing, type of modality, type of technology, end-user, and geographical regions.
By Type of Offering
- Consumables
- Instruments
- Services
By Type of Testing
- Virus Safety Testing
- Mycoplasma Testing
- Sterility Testing
- Endotoxin Testing
- Bioburden Testing
- Other Testing
By Type of Modality
- Antibodies
- Vaccines
- Cell Therapies
- Gene Therapies
- Biosimilars
- Traditional viral-based Therapies
- Proteins
- Other Modalities
By Type of Technology
- Polymerase Chain Reaction
- Traditional Techniques
- Chromatographic and Electrophoretic Techniques
- Next-Generation Sequencing
- Other Technologies
By End-user
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations / Contract Development and Manufacturing Organizations
- Academic and Research Institutes
By Geographical Regions
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
- Middle East and North Africa
- Saudi Arabia
- Egypt
- Rest of Middle East and North Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Pay Only for What You Need – The Best Way to Optimize
